[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
12.3 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]
Deals

Samsung’s Galaxy Watch 7 with LTE connectivity hits $300 Amazon low today, more up to $167 off

9to5Toys.com - 0
We have been tracking some solid price drops on Samsung’s new Galaxy Watch 7 wearables over the last few weeks, but Amazon is now offering its best prices yet on the most affordable LTE-ready models alongside ongoing discounts across the rest of the co...
Deals

Logitech’s new G309 LIGHTSPEED wireless gaming mouse is down to $70 today

9to5Toys.com - 0
We are now tracking a deal that drops Logitech’s new G309 LIGHTSPEED gaming mouse in black to $69.99 shipped on Amazon. This is a fairly new unit that debuted a few months back in July this year carrying an $80 price tag. We saw the white variant of th...
News

Bloodborne Can Run At 4K Resolution, 100 FPS on an RTX 4070 With ShadPS4 Emulator Latest Version

Wccftech.com - 0
The latest version of the ShadPS4 emulator continues to improve Bloodborne's performance on PC, fixing a critical issue and more. As showcased by GAMESMARK in a new video, version 0.4.1 of the emulator, which is not yet available to the public, runs the game with full audio and no longer requires a mod workaround to work properly. Performance seems to be extremely solid as well, as the game runs at 4K resolution and around 100 FPS on a system powered by an AMD Ryzen 5 7600X CPU, an RTX 4070 GPU, and 32 GB of DDR5 RAM. The latest public […]
Deals

First Amazon price drops on the new M4 Mac mini now live, but you might be better off at Best Buy

9to5Toys.com - 0
We aren’t talking about massive price drops here, and nothing quite as good as the elevated trade-in values we featured at Best Buy, but Amazon has shaved the MSRP on Apple’s new M4 Mac mini ahead of release this week. If you have gear to trade-in for ...

Nintendo Switch 2 is Unlikely To Be Revealed Before the End of the Year

Today only: Save a big-time $350 on the Samsung 14-inch Galaxy Tab S9 Ultra at $850

Score Alienware’s 27-inch 1440p 180Hz gaming monitor at its best price of $250 today ($125 off)

Amazon now offers first cash deals on Apple’s new M4 iMac configs ahead of this week’s release at $49 off

Elden Ring Gets Free AMD FSR 3 Frame Generation Mod

Dimensity 8400 CPU Cluster Details Shared By A Tipster; New Specifications Information Reveal An All-Performance Core Configuration, But Excludes The Cortex-X925

Anker Gear Up for Black Friday sale now live: Buy 2 extra 20% off, Buy 3 extra 25% off, mystery gifts, more

Call of Duty: Black Ops 6 Witnesses 52% Of Total US Xbox Players Checking It Out, a New Record

Target’s Day 5 Black Friday Deals now live: 50% off headphones, sparkling water, BOGO 50% groceries, more from $1

Age of Empires II Definitive Edition Might Be Coming to PlayStation

NVIDIA GeForce RTX 50 “Blackwell” Gaming GPUs Reportedly Launching “Soon”

Nintendo Cuts Yearly Forecast After Another Weak Switch Quarter

ASUS ROG Engineer Demonstrates DDR5 8800 MT/s “Gear 2” UDIMM Having Better Performance & Latency Than 9600 MT/s “Gear 4” CUDIMM

Apple Planning A “True Overhaul” Of The 2026 MacBook Pro With Major Design Refresh, Slated To Be Thinner With OLED Displays, And M6 Chip

Apple’s 2025 iPad Air Rumored To Be The Company’s First Tablet To Feature The M3, And The Possibility Of A 90Hz Display Which Could...

Intel Core Ultra 9 285H “Arrow Lake” CPU Tested, 16 Cores In Dell Pro Max 16 Laptop, Up To 28% Faster Than 185H “Meteor...

Slitterhead – How to Get Rarity Edo to Unlock Hidden Cave RE 2nd Loop Mission

A Primer On The Tech Policies Championed By The Trump And Harris Campaigns

AMD’s “Strix Point” Ryzen AI 9 HX 370 APU Handheld Gets Tested, Achieving 50-60 FPS At Black Myth: Wukong Under 15W TDP

Slitterhead – How to Easily Defeat Special Forces Unit Members

News

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

Wccftech.com - 0
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
Read more
News

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

Wccftech.com - 0
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]
Read more
News

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

Wccftech.com - 0
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]
Read more
News

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

Wccftech.com - 0
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]
Read more
News

Morgan Stanley: Oral GLP-1 Weight Loss Drug Can Propel Eli Lilly and Company to a $1 Trillion Valuation

Wccftech.com - 0
Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley. $LLY Eli Lilly Has Upside, May Reach $1 Trillion, Says Morgan Stanley (Bloomberg) - PT raised to a Street-high $950 from $805; shares closed at $757.78 on Thursday pic.twitter.com/0LgV0KfrLv — Christian Fromhertz 🇺🇸 (@cfromhertz) February 16, 2024 To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the […]
Read more
News

Eli Lilly and Company’s Tirzepatide GLP-1 Agonist For Weight Loss Reverses Fatty Liver Disease in a “Clinically Meaningful” Way

Wccftech.com - 0
Hardly a week seems to go by without something positive emerging from either Eli Lilly and Company (LLY) or its other major competitor, Novo Nordisk (NVO), on the prospects of the GLP-1 weight loss drugs. The ongoing week has again held true to this emerging bullish regimen, with Eli Lilly garnering significant positive developments in the battle to counter Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops most often due to metabolic disorders, including obesity and diabetes. This accumulation […]
Read more
News

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

Wccftech.com - 0
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
Read more
News

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

Wccftech.com - 0
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Read more
News

Want To Find Out the Level of Hype Surrounding the GLP-1 Weight Loss Drugs? Just Look at This Comparison Between Eli Lilly and Company...

Wccftech.com - 0
The burgeoning hype around GLP-1 weight loss drugs as a panacea for the obesity pandemic has propelled Eli Lilly and Company (LLY) shares to previously unimaginable zeniths while leaving Pfizer (PFE), a former darling of the pharma world, in the proverbial dust bowl. One of the most eye-opening charts you'll see right now, this shows Eli Lilly's $LLY price to sales ratio vs Pfizer's $PFE price to sales ratio over time. Lilly is up to 18x versus Pfizer's 2x. The two were roughly the same in early 2021. pic.twitter.com/g9ycAWBEiM — Bespoke (@bespokeinvest) January 19, 2024 As is shown in the […]
Read more
News

Eli Lilly and Company (LLY) Comes Out Against the Use of GLP-1 Drugs for “Cosmetic Weight Loss” as Obesity in the US Remains Near...

Wccftech.com - 0
Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice." To wit, Eli Lilly and Company has now published an open letter, noting among other things: "Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss." While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes: "Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has […]
Read more
News

Life-Long Commitment: A New Study Says That Over Half of the Weight Lost Through GLP-1 Drugs Such as Zepbound Comes Back After Quitting

Wccftech.com - 0
GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI. Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in […]
Read more
News

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

Wccftech.com - 0
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
Read more

Tag: Eli Lilly and Company

UGREEN early Black Friday sale now live with up to 47% off Qi2 MagSafe gear, power banks, bundle deals, more

Deals
The official UGREEN site has now launched an early Black Friday sale with some huge markdowns on various gear including its latest releases in the Uno series, power banks, travel chargers, and much more. While much of this gear is matched at the brand’...

Apple’s originally $1,199 M2 MacBook Air with 16GB of RAM is now down at $799 shipped

Deals
As many of you already know by now, Apple’s has upgraded all current generation Macs to start with 16GB of RAM (finally). However, this also carried back to the now previous-generation M2 MacBook Air models as well. While we are indeed now tracking ext...

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

News
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

News
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

News
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

News
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]

Morgan Stanley: Oral GLP-1 Weight Loss Drug Can Propel Eli Lilly and Company to a $1 Trillion Valuation

News
Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley. $LLY Eli Lilly Has Upside, May Reach $1 Trillion, Says Morgan Stanley (Bloomberg) - PT raised to a Street-high $950 from $805; shares closed at $757.78 on Thursday pic.twitter.com/0LgV0KfrLv — Christian Fromhertz 🇺🇸 (@cfromhertz) February 16, 2024 To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the […]

Eli Lilly and Company’s Tirzepatide GLP-1 Agonist For Weight Loss Reverses Fatty Liver Disease in a “Clinically Meaningful” Way

News
Hardly a week seems to go by without something positive emerging from either Eli Lilly and Company (LLY) or its other major competitor, Novo Nordisk (NVO), on the prospects of the GLP-1 weight loss drugs. The ongoing week has again held true to this emerging bullish regimen, with Eli Lilly garnering significant positive developments in the battle to counter Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops most often due to metabolic disorders, including obesity and diabetes. This accumulation […]

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

News
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

News
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]

Want To Find Out the Level of Hype Surrounding the GLP-1 Weight Loss Drugs? Just Look at This Comparison Between Eli Lilly and Company...

News
The burgeoning hype around GLP-1 weight loss drugs as a panacea for the obesity pandemic has propelled Eli Lilly and Company (LLY) shares to previously unimaginable zeniths while leaving Pfizer (PFE), a former darling of the pharma world, in the proverbial dust bowl. One of the most eye-opening charts you'll see right now, this shows Eli Lilly's $LLY price to sales ratio vs Pfizer's $PFE price to sales ratio over time. Lilly is up to 18x versus Pfizer's 2x. The two were roughly the same in early 2021. pic.twitter.com/g9ycAWBEiM — Bespoke (@bespokeinvest) January 19, 2024 As is shown in the […]

Eli Lilly and Company (LLY) Comes Out Against the Use of GLP-1 Drugs for “Cosmetic Weight Loss” as Obesity in the US Remains Near...

News
Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice." To wit, Eli Lilly and Company has now published an open letter, noting among other things: "Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss." While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes: "Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has […]

Life-Long Commitment: A New Study Says That Over Half of the Weight Lost Through GLP-1 Drugs Such as Zepbound Comes Back After Quitting

News
GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI. Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in […]

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

News
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
12Page 1 of 2

Recent articles

spot_img

©Patti.tech 2022